FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2368-2371 November 30, 2006 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kent, D. M. Related Article by The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators PubMed Citation

To the Editor: In the August 10 issue, Amarenco et al. report the results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study.¹ The study of high-dose atorvastatin for stroke offers promising results, but also raises some serious concerns. One concern is that 55 patients who received high-dose atorvastatin, as compared with 11 who received placebo, had liver enzyme elevations that were more than three times the upper limit of the normal range. These results mirror those of a previous study of high-dose atorvastatin in which liver enzyme elevations occurred six times more often with high-dose atorvastatin . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.